Objective Belimumab has been proven to be effective for treating refractory lupus nephritis. However, the meaningful renal ...
Objectives To estimate the risk of venous thromboembolism (VTE) in a nationwide cohort of newly diagnosed patients with SLE ...
Objective Fibromyalgia (FM) frequently co-occurs with SLE, but its independent contribution to musculoskeletal risk is ...
Objective Childhood-onset SLE (cSLE) is often described as more severe than adult-onset disease (aSLE) based largely on cross ...
Objective We aim to assess the cerebral oxygen extraction fraction (OEF) changes in patients with systemic lupus erythematosus (SLE) and neuropsychiatric SLE (NPSLE) by using an MRI-based technique ...
Objectives In Breakfree-1 (NCT05869955), BMS-986353 (CD19 NEX-T®), a CD19-directed CAR T cell therapy, showed promising early safety and efficacy in severe, refractory SLE. We report updated data for ...
Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are ...
Objective Two recent important lupus nephritis trials reported that proteinuria was a good predictor of renal outcome in Caucasians, but data on real-life situation, other races and severe nephritis ...
Objective Autoimmune haemolytic anaemia (AIHA) occurs in approximately 5–10% of patients with SLE and it is traditionally associated with higher disease activity, increased damage accrual and reduced ...
Objective To characterise the clinical, immunologic and molecular genetic features of monogenic lupus in a large, ethnically diverse paediatric cohort and to evaluate genotype-phenotype correlations.
Objective Complement plays a major role in SLE. Complement participation has been linked to disease activity and damage. Our objective was to estimate the association of complement behaviour with ...
Background Litifilimab is a humanized IgG1 monoclonal antibody targeting BDCA2, a receptor predominantly expressed on plasmacytoid dendritic cells (pDCs). In Part A of the Phase 2 LILAC study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results